Antibody maker Epitomics this week announced that it has signed a contract with SAIC-Frederick to develop several dozen rabbit monoclonal antibodies to support the Clinical Proteomic Technologies for Cancer program.
The work will focus on developing antibodies to tryptic peptides derived from protein biomarkers in human plasma. The antibodies will be used for immuno-enrichment of target peptides in mass spec workflows like stable isotope standards and capture by anti-peptide antibodies, or SISCAPA, and immuno-MALDI mass spec.
Epitomics has completed the first phase of the project, which called for it to generate and affinity-purify polyclonal antibodies against the biomarkers. In the current phase it will generate monoclonal antibodies against biomarkers validated during Phase 1.
CPTC is a five-year, $104 million effort to develop proteomics tools and technologies to accelerate discovery and clinical research. In July SAIC-Frederick signed a deal with Precision Antibodies to provide antibody and antigen characterization of antibodies used in the CPTC initiative, which followed on a contract Precision won from SAIC-Frederick in 2009 to develop monoclonal antibodies for the program (PM 07/30/2010).